German Biotechnology Report

German Biotechnology Report 2026

Beyond Grants and Venture Capital: Rethinking Innovation Financing in German Biotechnology

Germany’s biotechnology sector is among the most innovation‑intensive in Europe. At the same time, it is characterized by long development cycles, high capital requirements and substantial regulatory complexity. Public funding instruments therefore play a central role—not merely as supplementary financing, but increasingly as a strategic component of corporate development.

Alongside venture capital, strategic partnerships and project‑based grants, the German R&D tax allowance has emerged as a particularly relevant instrument. In practice, however, its strategic potential is still far from fully utilized. Used deliberately, the R&D tax allowance can become more than a fiscal side effect. It can function as a structural stability anchor within the innovation and financing architecture of biotech companies.

The R&D Tax Allowance as a Stability Anchor

With the introduction of the R&D tax allowance, Germany has established a policy instrument of exceptional strategic relevance whose significance is still widely underestimated. Few funding instruments combine stability, predictability and legal certainty to a comparable extent—qualities that are crucial for research‑intensive biotech companies. The tax‑exempt allowance remains entirely within the company, creates immediate liquidity and avoids downstream tax effects common to traditional grants. Unlike conventional funding programmes, it is neither budget‑capped nor competitive and operates independently of funding cycles, shielding companies from political and fiscal volatility. Once project eligibility is confirmed, the legally binding decision provides a robust foundation for long‑term budget, personnel and investment planning. Taken together, these features position the R&D tax allowance as one of Germany’s most structurally stable innovation funding instruments.

From Retrospective Refund to Strategic Planning Tool

Despite its structural strengths, the R&D tax allowance is still predominantly viewed retrospectively by many companies – as a tax credit for R&D costs already incurred. This perspective falls short and leaves a substantial part of its strategic potential untapped. Its true value emerges only when the R&D tax allowance is embedded proactively into long‑term financial planning. When used effectively, the R&D tax allowance functions like a financial baseline for continuous research. It extends runways, reduces dependence on volatile financing windows and creates strategic room for manoeuvre – particularly in early and mid‑stage development phases, where planning certainty is a decisive success factor. In this way, the R&D tax allowance evolves from a retrospective funding mechanism into a core pillar of a long‑term financing architecture, gaining relevance precisely where stability and reliability are indispensable for sustainable innovation.

From Isolated Funding to a Coherent Financing Architecture

Biotech companies increasingly need to align national funding programmes, European instruments and tax incentives within a coherent long‑term strategy. Yet funding is still often pursued in isolation, without being systematically embedded in development roadmaps or investor communication.

A more effective approach treats public funding as a multi‑year financing architecture aligned with the underlying R&D programme. Within this framework, instruments play complementary roles: project‑based grants support defined milestones, while the R&D tax allowance stabilises the continuous research backbone of an organisation. Combined strategically, these instruments create planning security and resilience – an increasingly critical factor given rising development timelines and capital requirements. For Germany as a biotech location, the impact of public funding therefore depends less on its availability than on its strategic integration into corporate planning.

A Growing Risk: Increasingly restrictive administrative practice threatens to weaken the stabilizing function of the R&D tax allowance

Despite its robust legislative design, the administrative interpretation of the R&D tax allowance has recently narrowed the scope of eligible activities – particularly to the detriment of biotechnology and clinical research. This development is not rooted in a change of law, but in a shift in administrative interpretation that has occurred at the level of the assessment and certification process.

Since 2024, eligibility assessments have increasingly been based on the requirement that external R&D contractors must demonstrably develop independent scientific or technical solution pathways within the scope of their mandate in order for their activities to qualify as eligible expenditure. As a consequence, a wide range of scientifically indispensable but operationally standardized R&D services is now routinely excluded from eligibility – despite having been explicitly considered eligible at the time the R&D tax allowance was introduced.

This interpretation pattern was also explicitly addressed in the context of the Pharmadialog:

“In the context of the Pharmadialog with the Federal Ministry of Health, it became clear that the current restrictive treatment of certain R&D services under the R&D tax allowance is not the result of legislative change, but of an administrative interpretation introduced in 2024. In particular, the exclusion of core clinical research services – such as monitoring or project management – when performed by CROs, while allowing the same activities when carried out by sponsors, was highlighted as difficult to justify from a scientific and regulatory perspective.” (Personal communication with Martin Krauss, President of the German CRO Association (BVMA) and Managing Director of FGK Clinical Research, following the Pharmadialog with the Federal Ministry of Health (BMG) and the Federal Ministry of Research, Technology and Space (BMFTR), organized by the German Aerospace Center (DLR) on behalf of BMG/BMFTR. The statement reflects discussions with ministerial representatives and industry associations (including BVMA, BPI and vfa) regarding the administrative interpretation of the German R&D tax allowance)

This affects, in particular, core elements of modern biotechnology research such as sequencing, bioinformatics analyses, protein analytics, functional assays and other highly specialized external services. In practice, these activities are frequently classified as non‑eligible on the grounds that they are deemed to constitute “standardized services”, even though they are central components of scientific problem‑solving and critical to achieving the project’s research objectives. A comparable interpretation pattern has emerged in clinical research. Essential activities such as study coordination, monitoring, regulatory interactions or project management are increasingly categorized as “administrative” and therefore excluded from eligibility – unless they are performed directly by the sponsor itself. When the same activities are carried out by specialized CROs, they are frequently denied eligibility, despite representing core elements necessary to ensure scientific validity, data integrity and regulatory robustness of clinical development programmes.

This practice has led to a systematic asymmetry: while standardized CAPEX investments are often recognized as eligible even in the absence of significant scientific uncertainty, knowledge‑, expertise‑ and process‑driven R&D activities are excluded solely based on the organizational form of their execution. The result is a structural distortion that disadvantages precisely those sectors – biotechnology and clinical research – that rely on highly specialized external expertise as a prerequisite for innovation.

If the R&D tax allowance is to remain a central, reliable and innovation‑enabling instrument, its application must return to a practice‑oriented and technology‑neutral interpretation. Scientific problem‑solving must be recognized as such regardless of whether it is performed internally or by specialized external R&D contractors. Otherwise, a legally robust instrument risks losing its effectiveness not by legislative intent, but through administrative practice.